This ain’t your grandpa’s acid trip…

“Microdosing” has been one of the biggest (and largely unreported) trends in Silicon Valley over the last decade.

And like many other Valley creations that once seemed crazy… it’s on the verge of going mainstream.

In fact, scientists are now validating some of the claims made by microdosing advocates.

That could open up significant profit potential for early investors.

But before we get to that, let’s talk about microdosing itself…

The 21st Century Way to Take Psychedelics

Creative types using illegal substances is nothing new… especially in the San Francisco area.

Steve Jobs famously said taking LSD was one of the most important things he’d ever done in his life.

As the name suggests, microdosing is the process of taking relatively small amounts of a substance over a more extended period.

The term has come to specifically apply to potent psychedelic compounds known for producing hallucinogenic effects – everything from iboga (derived from a shrub) to psilocybin (the active component in so-called “magic mushrooms”).

Perhaps the most popular choice is lysergic acid diethylamide (LSD), commonly known as “acid”…

A regular user looking for the quintessential trip – replete with altered levels of perception, including visual or auditory hallucinations – might ingest somewhere between 50–200 micrograms in a single dose.

In contrast, a microdoser could take just 8–15 micrograms in a single dose, typically repeating the process on different days over several weeks or months.

The idea is often credited to James Fadiman, a psychologist and psychedelic researcher who came up with a widely-followed microdosing protocol and wrote 2011’s The Psychedelic Explorer’s Guide.

The approach was further popularized to mainstream audiences with Ayelet Waldman’s 2016 book, A Really Good Day, which chronicles the author’s month-long microdosing experiment following Fadiman’s guidelines.

Fadiman and his team are now collecting user-submitted reports through their website,… and some of the anecdotal evidence is promising.

Microdosers report feeling mentally sharper, higher creativity levels, increased satisfaction with their lives, and other positives.

From Bay Area to Wider Adoption

Of course, for psychedelics to gain any real scientific credibility or commercial applicability – including a change in the Schedule I legal status assigned by the federal government – more controlled studies are needed.

According to the government, Schedule I drugs have a high potential for abuse and no currently accepted medical treatment use in the U.S. Drugs in this category include marijuana and MDMA.

Daily editor Teeka Tiwari and his team believe psychedelics will eventually be reclassified as Schedule III.

Drugs in this category have medical use… but may lead to moderate or low physical dependence or high psychological dependence.

Schedule III classification would put psychedelic substances in the same category as drugs like Tylenol with codeine, anabolic steroids, and Vicodin. They’d still be regulated… but would also be recognized for their medical benefits.

Research in psychedelic compounds shows they can treat some of the most serious and expensive mental health conditions in the world… And they do it better than traditional medicines.

For instance:

  • In 2019, the FDA gave a “breakthrough therapy” designation to the Usona Institute, which uses psilocybin to treat major depressive disorder (MDD). The condition causes a persistent feeling of sadness and loss of interest.

  • Pharma giant Johnson & Johnson recently released its own FDA-approved drug, Spravato, to treat people suffering from depression. It’s a fast-acting nasal spray that uses a chemical cousin of ketamine, the so-called party drug “Special K.”

  • In 2019, the Department of Veteran Affairs approved ketamine for the treatment of PTSD.

In particular, this latter breakthrough offers hope to the 2.7 million registered Vietnam War veterans… 660,000 Gulf War vets… and 300,000 Enduring Freedom vets who have PTSD.

Right now, the rate of retired and active-duty military personnel taking their own lives is a staggering 20.6 times per day. This approval could help lower that rate and save thousands of lives.

Former VA secretary Robert Wilkie hailed this milestone:

We’re pleased to be able to expand options for veterans with depression who have not responded to other treatments. It reflects our commitment to seek new ways to provide the best health care available for our nation’s veterans.

So, by all appearances, we’re at an inflection point where substances that were once completely derided are now considered legitimate medicines.

And that’s our opportunity to profit…

Be Early and Right

Today, individual investors in the psychedelics space have an early advantage over institutions. That’s because institutions have to wait until stocks are large enough to trade on the world’s biggest exchanges.

This gives you the opportunity to get in before the institutions… And puts you in a position to be way ahead as these companies grow and a storm of big money finds its way into this space.

We saw a similar scenario play out when early investors made fortunes by getting into the crypto market before institutions. Once crypto adoption started to take off, certain tiny tokens exploded.

So, if you’re looking to take advantage of the opportunity in psychedelic therapeutics, my advice is to get positioned right now… before Wall Street can participate.

And that’s why last Thursday, Teeka held a presentation to show you why psychedelic therapies are his next trillion-dollar trade.

During this event, Teeka explained how psychedelic medicines are solving a global mental health epidemic costing society nearly $3 trillion per year in health expenses and lost productivity.

He also introduced his new partner on this project, Mike “Zappy” Zapolin.

Zappy’s a multimillionaire investor – and former Wall Street vice president – featured in VicePlayboy… and Fox News. And when it comes to Teeka’s next trillion-dollar trade, he’s the most connected man in the space.

He’s a man whom athletes, movie stars, world-class doctors, and even Oprah Winfrey rely on as the most trusted source of information in this emerging trillion-dollar trend.

And he’s joined Teeka to show you how to unlock life-changing gains from psychedelic therapeutics… including how to access five stocks they believe could potentially pull forward 100 years’ worth of average stock market gains in 18 months.

Zappy has earned a reputation as the “psychedelic concierge to the stars” because of his advanced insight into psychedelic therapeutics and new investment opportunities.

If you’re still skeptical about psychedelic treatments like microdosing… I encourage you to watch his presentation with Teeka.

You’ll learn how these therapies could cure millions of people suffering from mental health disorders – and make early investors fortunes.

Best wishes,

Nilus Mattive signature

Nilus Mattive
Analyst, Palm Beach Daily